The U.S. Patent No. 9,790,208 for daridorexant is set to expire on October 25, 2033 [1]. This patent is associated with the drug also known as daridorexant, which is used to treat insomnia [2].
When does patent protection for daridorexant end?
Daridorexant's primary U.S. patent, U.S. Patent No. 9,790,208, is scheduled to expire on October 25, 2033 [1]. This expiration date marks a point when generic competition may potentially enter the market, provided no other forms of market exclusivity or additional patents are in place.
What is daridorexant and what is it used for?
Daridorexant is a dual orexin receptor antagonist used for the treatment of insomnia [2]. It works by blocking the action of orexin, a neurotransmitter that promotes wakefulness [3].
Are there any other patents protecting daridorexant?
While U.S. Patent No. 9,790,208 is a key patent, pharmaceutical companies often secure multiple patents covering various aspects of a drug, including different formulations, manufacturing processes, or new uses. Information on the full patent landscape for daridorexant, including any additional patents and their expiration dates, can be found on DrugPatentWatch.com [4].
What happens when a drug patent expires?
Upon patent expiration, other companies may be able to seek approval to manufacture and sell generic versions of the drug. This typically leads to a decrease in the drug's price due to increased competition. For daridorexant, the expiration of U.S. Patent No. 9,790,208 in 2033 opens the door for potential generic entry after that date.
Who developed daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals [2].
What is the mechanism of action for daridorexant?
Daridorexant functions as a dual orexin receptor antagonist. It inhibits the binding of orexin-A and orexin-B to the OX1R and OX2R receptors in the brain. Orexin is a neuropeptide that plays a role in regulating wakefulness, and by blocking its receptors, daridorexant reduces the signaling that promotes being awake [3].
What are the potential risks or side effects of daridorexant?
Common side effects of daridorexant include somnolence and headache. It is also associated with a risk of sleep paralysis and hypnagogic or hypnopompic hallucinations. Due to its CNS depressant effects, patients are advised to avoid operating heavy machinery or engaging in hazardous activities requiring full alertness [2].
How does daridorexant compare to other insomnia treatments?
Daridorexant belongs to a class of drugs known as orexin receptor antagonists, which differ from older insomnia medications like benzodiazepines or non-benzodiazepine hypnotics by targeting the wakefulness system rather than acting as general sedatives [3]. This mechanism is believed to offer a different profile in managing insomnia.
Where can I find more information on drug patents?
Detailed information regarding drug patents, including expiration dates and patent landscapes for specific medications like daridorexant, is available through resources like DrugPatentWatch.com [4].
Sources:
1. US Patent 9790208
2. Idorsia Pharmaceuticals. (n.d.). DARIDOREXANT.
3. [Information on the mechanism of action of daridorexant is generally available in drug information databases and scientific literature. Specific citations are not provided in the source material for this aspect.]
4. DrugPatentWatch.com